Abstract
This protocol describes the design of an international study to examine the potential prophylactic effect of 14 days of diltiazem therapy to prevent early reinfarction in patients initially presenting with non-Q-wave acute myocardial infarction. Reinfarction was defined by the detection of a secondary elevation of plasma MB-creatine kinase. The results of clinical trials, instrumental in this protocol design, that established the increased propensity for early reinfarction after initial non-Q-wave infarction are described and the implications of the present study are discussed.
Original language | English (US) |
---|---|
Pages (from-to) | 906-910 |
Number of pages | 5 |
Journal | The American journal of cardiology |
Volume | 58 |
Issue number | 10 |
DOIs | |
State | Published - Nov 1 1986 |
Funding
Participating institutions and personnel are listed in the Appendix. This study is supported by a grant from Marion Laboratories, Inc., Kansas City, Missouri. Manuscript received April 23, 1986; revised manuscript received July 7, 1986, accepted July 8, 1986.
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine